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Debatable Edibles: Bioengineered Foods
Picture a herd of30,000 pigs bred from fer-
tilized eggs injected with human genetic
material. They look and smell like normal
pigs. If you needed an emergency transfu-
sion, you would no doubt be grateful for
clean, disease-free blood from these trans-
genic pigs. And, ifyou desperately needed a
kidney, you might be thrilled to receive one
from a pig.
But what about a thick, juicy transgenic
pork chop? The meat would be leaner than
traditional pork, and sales could help pig pro-
ducers ofthe future cover high research costs.
Ready for dinner? Ifyou answered, "no way,"
you're not alone, says Alvin Young, director
of the U.S. Department of Agriculture's
Agricultural Biotechnology Office.
Whenever he talks to college students,
Young routinely gauges public response to
transgenic research. Three-fourths of the
students who take part in Young's informal
surveys tend to be enthusiastic about the
possibility of life-saving medical products
from pigs. Ask them about transgenic meat,
though, and 85-90% ofthe students quick-
ly turn up their noses. "Most just have a gut
feeling that they don't like the idea," Young
muses. "Could they get over it? I think they
could." In his meetings with students,
Young addresses the most critical question
currently facing food biotechnologists: will
consumers actually buy genetically engi-
neered foods?
The world may soon learn the answer to
that question. Calgene, Inc. of Davis,
California, will begin selling a genetically
engineered tomato this year. Dubbed the
"Flavr Savr," Calgene's invention will be the
first "whole" biotech food on the market.
Because a section of its genetic code has
essentially been spliced, flipped, and rein-
serted, the Flavr Savr stays fresh up to 10
days longer than conventionally grown vari-
eties, says Carolyn Hayworth, Calgene's
manager ofinvestor and public relations.
In May this year, a final decision by the
FDA gave Calgene the go-ahead to market
Flavr Savr, ending the tomato's long, ardu-
ous journey from the lab bench to the mar-
ketplace. Along the way, the company has
repeatedly been at the center ofheated pub-
lic debate about bioengineered foods.
Clearing so many hurdles has clearly taken a
toll on the company: for the six-month peri-
od ending 31 December 1993, Calgene
posted a whopping net loss of$21,192,000,
compared to a net loss of $11,104,000 for
the second halfof1992.
Research at companies like Calgene
promises fresher, hardier, more disease-resis-
tant foods, according to Edward N. Brandt
Jr., director ofthe Center for Health Policy
at the University of Oklahoma Health
Sciences Center. "You also have the possibil-
ity of additional nutrient fortification of
foods," adds Brandt, chair of the FDA's
Food Advisory Committee, which reviewed
Calgene's safety data.
The potential benefits of bioengineered
foods have been touted by such respected
authorities as the World Health Organ-
ization and the American Dietetic Associ-
ation. Indeed, researcher Thomas J. Hoban
IV ofNorth Carolina State University notes
that biotechnology "has the potential to
improve agricultural productivity and
enhance the food supply."
Biotechnology critics disagree, charging
Questionable concoctions? Scientists are whipping up new foods in the laboratory that may be both ben-
eficial and harmful.
that companies like Calgene are more con-
cerned with making money than feeding
Americans. The Pure Food Campaign insists
that products such as bovine growth hor-
mone only add to the nation's food surplus,
while subjecting consumers to unnecessary
health risks. Foods like the Flavr Savr, which
is expected to cost about $1 more per pound
compared to conventionally grown tomatoes,
won't help feed the world's hungry, says
Ronnie Cummins, the group's U.S. national
director. "We have not heard ofa single [bio-
engineered] food product that's designed for
anything other than to enhance the profits of
the company," Cummins charges.
More moderate groups such as the
Environmental Defense Fund, meanwhile, are
pushing for tougher regulatory control and
labeling of biofoods. Joan Gussow, professor
of nutrition and education at the Teachers
College ofColumbia, worries about the envi-
ronmental consequences of bioengineering.
Scientists generally agree, for instance, that
"super-resistant" insects will evolve in
response to genetically engineered crops con-
taining Bacillus thuringiensis, a natural soil
bacterium that generates an insect-fighting
protein. Some believe, however, that insect
resistance to such crops can be controlled.
Others aren't so sure. "Everybody
behaves as if magically, science will find a
way," says Gussow, author of Chicken Little,
Tomato Sauce, andAgriculture. "My answer
to that is that technological rabbits have big,
noxious droppings. We're always hoping that
the next technology will clean up the mess
we made with the last one. I think biotech is
being viewed as the solution to the problems
we createdwith high-tech agriculture."
A Rough Trip for Flavr Savr
Conventional tomatoes are so fragile that
they must be shipped green. After reaching
supermarkets, they're zapped with ethylene
gas, the natural ripening agent in tomatoes.
To make hardier tomatoes, Calgene devel-
oped an ingenious process involving a half-
dozen basic steps.
First, researchers isolate or clone the
polygalacturonase (PG) gene, which causes
tomatoes to soften and rot. Next, they flip
the PG gene into an "antisense" position.
The PG gene must then be combined with a
marker gene that works like the crosshairs
on a rifle, targeting a section of the tomato
genome. (In the case of the Flavr Savr,
Calgene's marker is the kanamycin-resistant
gene, which helps E. coli bacteria fight off
the deadly effects of antibiotics.) Thus
marked, the reversed PG gene is introduced
into agrobacterium and placed in a petri
dish with tomato leaves. After the leaves are
infected with agrobacterium, they form new
plants containing the reversed PG gene.
Calgene's safety data were scrutinized
by the FDA in April. FDA Food Bio-
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technology Coordinator James
H. Maryanski said that the Flavr
Savr appears to be safe. A final
ruling in May approved the
tomato's usage.
Questions have been raised,
however, about the kanamycin-
resistant gene. Some fear this
marker gene could possibly find
its way into nearby soil microbes
or even into the human digestive
tract, resulting in a dangerous
resistance to antibiotics. Such a AlvinYouni
scenario is unlikely because the have a gu
marker gene is rapidly degraded, don't like t
Maryanski says. Yet, he con- engineered
cedes, "there is a very low proba-
bility" that the marker gene could somehow
turn up in the wrong place.
Critics also worry about three 28-day
toxicity studies in which rats were gavaged,
or force-fed tomatoes. In the second and
third of these studies, gastric erosion was
noted in some animals, but Calgene says
those symptoms had nothing to do with the
Flavr Savr. "These erosions were minute,
pinpoint-sized erosions," explains Calgene's
Hayworth. "They occurred in rats that were
fed water only, as well as rats that were fed
conventional tomatoes only."
As a result ofthe Flavr Savr controversy,
current FDA approval procedures and food
labeling laws are once again claiming the
limelight. Unlike food additives, mostwhole
foods don't require FDA approval,
Maryanski explains. Consequently, geneti-
cally engineered tomatoes aren't subject to
premarket review, and they don't need to be
labeled. (In fact, Calgene approached the
FDA voluntarily, to make sure its product
would complywith all consumer safety stan-
dards.)
"If the gene you're using is a tomato
gene that's been introduced into corn, and
that protein has been safely consumed in the
past, then we're not going to treat those as
new food additives," Maryanski says. That's
because such products would be classified by
the FDA as "GRAS," or "generally recog-
nized as safe," he adds.
Exceptions to the FDA's current regula-
tory system include bioengineered foods
containing potential toxins or common
allergens. For example, if a new, frost-resis-
tant tomato contains DNA from a fish, that
product would have to be labeled because
the FDA recognizes that many consumers
are allergic to fish.
At the Environmental Defense Fund,
Senior Attorney D. Douglas Hopkins says
labeling, premarket testing, and registration
of bioengineered foods are essential to pro-
tect all consumers from potential allergens.
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"Genetically engineered foods are, for the
most part, added proteins," he says. "Food
allergens are virtually all proteins, and food
< allergies-many of them seri-
- ous-afflict between 2.5 mil-
lion and 5 million Americans."
Do consumers really want
more labels? Jim Altemus,
manager of plant science com-
munications for biotech giant
MonsantoofSt. Louis, Missouri,
says additional labeling would
only confuse consumers.
Instead of labeling, he says,
companies like Monsanto
-Most people must take responsibility for
feeling they educating consumers. "The
idea of bio- general public says they don't
ids. want labeling," Altemus says.
"When you ask them what
they want on their food containers, they're
the first ones to say, 'Don't put more six-
point type on containers in language I can't
understand."'
But a 1992 study by Hoban suggested
that consumer attitudes about labels are less
clearcut. In his survey of 1228 adults,
Hoban asked about the importance of dif-
ferent types ofinformation on labels. "Over
80 percent ofrespondents rated each type of
food label information as 'very important,"'
his report concludes. "These results support
the idea that people want more information
on a variety oftopics, including biotechnol-
ogy.
Hoban cautions, however, that the label-
ing issue is by no means black and white.
For instance, respondents generally seemed
to want labels on whole foods such as genet-
ically engineered tomatoes. Yet, some admit-
ted that labels on complex processed foods
such as ketchup might be confusing and
unnecessary.
MilkWars
Calgene's high-tech tomato may have set off
a few sparks, but recombinant bovine
growth hormone continues to fuel a raging
public debate. Also known as bovine soma-
totropin (BST), the hormone prompts cows
to produce 10-12% more milk. BST
entered the market in February ofthis year.
Since then, millions of BST injections have
been sold, reports Gary Barton, Monsanto's
director of environmental com-
munications.
Growth and lactation in
mammals are regulated by a nat-
ural hormone originating in the
pituitary gland. In the mid-
1980s, researchers learned that a
synthetic version of bovine
growth hormone also stimulates kd
lactation, partly by generating a
secondary hormone, insulinlike \);
growth factor-I (IGF-I). Today, N
Monsanto makes BST by Joan Guss
inserting a gene from cows into logical rab
E. coli bacteria, which multi- noxious droll
plies in fermentation tanks.
How safe is BST? In the 24 August
1990 issue of Science, researchers represent-
ing the FDA's Center for Veterinary
Medicine concluded that "the use ofrecom-
binant bovine growth hormone (rbGH) in
dairy cattle presents no increased health risk
to consumers." According to authors Judith
C. Juskevich and C. Greg Guyer, BST
doesn't appear to be biologically active in
humans. To prove their point, the authors
cited research from the 1950s in which
injections ofbovine growth hormone "were
not effective" as treatment for children suf-
fering from dwarfism-apparently because
animal growth hormone doesn't bind with
growth hormone receptors in human tissue.
They also described short-term oral toxicity
tests using rats.
After an exhaustive nine-year evaluation,
the FDA finally ruled in November 1993
that the meat and milk from BST-injected
cows is safe. "There is virtually no difference
in milk from treated and untreated cows,"
FDA Commissioner David A. Kessler told
TheNew York Times. "It's not possible using
current scientific techniques to tell them
apart." In fact, the FDA in February warned
dairy distributors to avoid labeling products
as "free" of BST, since untreated cows gen-
erate growth hormone, too.
Researchers like Bill von Meyer, presi-
dent of Fairview Industries, a genetics and
chemistry research company in Middleton,
Wisconsin, remain unconvinced of BST's
safety. Von Meyer, who reviewed
Monsanto's safety data after being contacted
by a concerned dairy farmer, says rodent
toxicity tests were much too briefand didn't
involve enough animals. Another scientist,
Samuel S. Epstein, a professor of occupa-
tional and environmental medicine at the
University of Illinois at Chicago, has sug-
gested a link between IGF-I-the secondary
hormone stimulated by BST use-and
breast cancer in humans. In a February 14
letter to Kessler, Epstein warned that "IGF-I
induces malignant transformation ofnormal
human breast epithelial cells." Infants are
particularly susceptible to cellular changes
caused by IGF-I, according to Epstein, who
also serves as chair of the
i Cancer Prevention Coalition.
'X After Epstein went public
R with his letter at a February
meeting ofthe American Assoc-
iation for the Advancement of
Science, Kessler received a
rebuttal letter from Dennis M.
Bier, a professor of pediatrics
and director of the Children's
Nutrition Research Center at
Baylor College of Medicine. "I
low
bits
ppin
-Techno- am aware ofno substantive evi-
s have big, dence in the world's scientific
Igs. literature that IGF-I causes
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malignant transformation ofnor-
mal human breast epithelial
cells," Bier told Kessler. In
response, Epstein cited Harris
and colleagues in the 13 August
1992 New EnglandJournal of
Medicine: "It now appears highly
likely that a series ofgrowth fac-
tors are responsible, at least in
part, for the evolution of normal
breast epithelia to breast cancer.
These factors include IGF-1."
Still, Monsanto and the FDA Jim Altem
say Epstein's fears are unfounded. labeling fo
"The consumption of dietary should ed
IGF-I plays no role in either ers.
inducing or promoting any human disease,
nor does it cause malignant transformations
of normal human breast cells," the FDA
announced in a March 16 news release.
The Pure Food Campaign and some
farmers say cows injected with BST are
more likely to develop mastitis, causing pus
to form in udders. "That raises questions
about extra antibiotic use," says Bruce Krug,
coordinator for the New York Farmers'
Union. Barton says, however, that mastitis
tends to occur in all highly productive cows.
"[Mastitis] is controlled by good manage-
ment," Barton says. "The better your farm-
ing operation, the less mastitis you have."
Noting that U.S. milk production
already exceeds the demand for it, Krug says
BST may force small dairy farmers out of
business. Sheldon Krimsky, chair of the
Department of Urban and Environmental
Policy at Tufts University, agrees with Krug.
"It's been demonstrated by economic analy-
sis that [BST] is likely to displace small
farmers," says Krimsky, who serves on the
board of directors for the Council for
Responsible Genetics.
But Monsanto says BST can give large as
well as small farming operations an econom-
ic boost. "The efficient producers are going
'us-
)ods
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High on the Hog? Biotech pigs produce leaner meat,
preferthe taste ofthe fattier roasts.
20 to benefit," Barton says. "It's
c
- $5.50 [per injection], so
- whether you have 100 or 1000
cows, your cost is proportional
to the size ofyour herd."
And consumers may actu-
ally support BST use. In a
January 1994 survey for the
Grocery Manufacturers of
America, Hoban concluded
that "the use of BST in milk
production will have no real
-Instead of impact on projected future
companies consumption ofmilk."
ite consum- Even so, some researchers
fear that the BST controversy
could adversely affect public opinion about
other genetically engineered foods. "I don't
like to see people judging the whole poten-
tial of biotechnology based on the example
ofBST," says Peggy G. Lemaux, an associate
cooperative extension specialist at the
UniversityofCalifornia, Berkeley.
Pigs as Bioreactors
"It looks like a pig, smells like a pig, and in
fact it tastes like pork. But biochemically,
it's something very different," says Norman
Steele, research leader for the USDA's
Nonruminant Animal Nutrition Lab,
describing pigs injected with bovine growth
hormone. The pigs are just one example of
current efforts to create transgenic livestock.
Compared to conventional pork, meat
from pigs containing bovine growth hor-
mone mayprovide more protein and less fat,
USDA researcher Vernon G. Pursel wrote in
the 16 June 1989 issue of Science. Other
possible benefits of transgenic livestock
include increased wool production by sheep
and improved disease resistance among
chickens.
Pursel has reported, however, that
bovine growth hormone-transgenic pigs
tend to suffer a litany of health ailments,
including gastric ulcers,
arthritis, and a shortened
lifespan. Such detrimental
l7 effects may seem too high a
price tag for sweeter pork
chops: But what if trans-
genic pigs served as a "fac-
tory" for more valuable
products? In the May 1993
issue of the Journal of
Animal Science, Pursel and
C.E. Rexroad, Jr. noted the
potential of transgenics as
bioreactors for rare medical
products.
1=77 S Genetically engineered
pGH pigs could someday pro-
duce human hemoglobin,
interferon for chemothera-
but consumers py, or even organs for trans-
plant into humans. But that
dream is far from reality. "The problem with
the transgenic approach at the present time
is that it can't be regulated adequately
enough to prevent detrimental effects,"
Pursel explains. "Many of the genes that
would be useful remain unknown. The
genes that are well known aren't well regu-
lated enough."
In addition to transgenic research,
researchers at the USDA and several corpo-
rations, such as Upjohn, Eli Lilly, and
American Cyanamid, are investigating the
use of porcine somatotropin (PST). Pigs
injected daily with PST for at least 30 days
pack on as much as 300 grams of muscle
protein per day, Steele reports. The result,
he says, is leaner, juicier pork chops.
Unfortunately, Steele notes, PST must be
injected daily. For a large pig producer, he
says, daily injections would be far too costly
and time consuming.
But consumers might be willing to cover
the cost ofPST injections. In a study of 120
families, KenJ. Prusa and colleagues at Iowa
State University concluded that "leanness of
meat was important to 98 percent of the
consumers, and 83 percent indicated that
theywould pay more for leaner pork ifavail-
able." Families were asked to taste test ham
roasts and loin roasts from PST-treated pigs
as well as control pigs. Overall, Prusa wrote
in the May-June 1993 issue oftheJournalof
FoodScience, PST loin and ham roasts were
as acceptable as meat. However, consumers
said the control ham roasts were juicier,
more tender, and more flavorful than the
PST-generated roasts.
Natural Pesticides and Herbicides
As the public grows increasingly concerned
about the use ofchemical pesticides and her-
bicides, companies like Monsanto are devel-
oping crops with natural defense mecha-
nisms. Among the strategies now being
investigated is the use of Bacillus thuringien-
sis, or Bt, in potatoes, cotton, corn, and other
crops. A natural soil bacterium, Bt fights off
insects byproducing aspecial protein.
Already, Bt crops have shown great
promise for reducing chemical pesticide use.
In a 1993 issue of Plant Molecular Biology,
JeffWyman and colleagues described a tech-
nique for enhancing Russet Burbank pota-
toes with a cryIIIA gene, which encodes for
Bt protein. Such transgenic plants effectively
kill juvenile Colorado potato beetles and
force adult beetles to stop feeding, Wyman
reports.
He readily admits, however, that insect
resistance to Bt crops is "almost inevitable."
To prevent widespread problems, resistant
beetle populations should be diluted with
nonresistant specimens, Wyman says.
Mixing transgenic and conventional seeds
also helps slow the evolution of super-resis-
tant pests, he adds.
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The good news, says researcher Fred
Gould ofNorth Carolina State University, is
that pests seem to develop resistance to sin-
gle groups of Bt toxins. Consequently, "as
insects become resistant to one Bt toxin,
that toxin could be successfully replaced by a
different Bt toxin," Gould wrote in the
September 1992 Proceedings ofthe National
AcademyofSciences.
Monsanto is also developing soybeans,
corn, and other crops that won't die when
they're sprayed with Roundup, aweed killer
classified by the EPA as noncarcinogenic.
Made by Monsanto, Roundup effectively
kills weeds, but it also kills surrounding
crops by interfering with photosynthesis,
explains Jim Altemus, manager ofplant sci-
ence communications at Monsanto.
Critics charge that Monsanto's research
will encourage increased use of Roundup.
"We hope it does," Altemus says. Unlike
manyherbicides, he notes, Roundup doesn't
cause cancer orharmwildlife.
Fantastic Possibilities
From disease-resistant chickens to potatoes
that don't bruise thanks to moth DNA, the
U.S. government dearly supports the devel-
opment ofbioengineered foods. For the fiscal
year 1994, the government will spend about
$211 million on biofood research, Young
reports. Mostoftheworkis beingdirected by
the USDA. Big business is also investing
heavily in bioengineered foods. For the calen-
daryear 1993, for instance, biotech company
DNA Plant Technology of Cinnaminson,
New Jersey, spent $13.4 million on research
and development. Calgene's R&D costs
came to $2.6million forthe same period.
For Young, biotechnology represents a
solution to the problem of an overcrowded
planet. "As the population continues to
increase, we will see a doubling of food
requirements, probably by 2020 or 2030," he
says. "The options available to us are either to
take more land for agriculture or figure out
how to increase the productivity of the land
we have." Biotech, Young says, can help U.S.
farmers achieve the goal of sustainable agri-
culture, which doesn't leave fields barren.
To support more
efficient, productive
farming, researchers
are engineering crops
to resist cold weather,
drought, pests, disease,
and spoilage, as well as
plants that can fix their
own nitrogen in soil,
reducing the need for
chemical fertilizers.
Lemaux and Yuechun
Wan, for instance, are
growing barley that
fights barley yellow
dwarfvirus. Everyyear,
You say potato ... Crop
natural defense mechanic
reduced need for pesticide
this virus wipes out 3% ofthe nation's barley
crop, explains Lemaux. Supported by the
Plant Gene Expression Center (ajointventure
ofthe USDA's Agricultural Research Service,
UC-Berkeley, and the California Agricultural
Experiment Station), Lemaux's research may
also provide a model for improving the viral
resistance ofwheat andoats.
Since the advent of biotechnology, two
key developments have set the stage for
genetic engineering of foods. First, Lemaux
explains, researchers learned to clone plants
from tissue culture. Second, they refined a
way to introduce DNA into cells by using
agrobacterium as a carrier. In the past, unfor-
tunately, researchers have found it difficult to
insert desirable genetic material into cereal
crops because agrobacterium isn't an effective
carrier for those types offoods. But Lemaux
and Wan successfully introduced aviral-resis-
tantgene into barleybyusinga "gene gun" to
fire genetic material into plantembryos.
The Pure Food Campaign opposes such
technologyand instead advocates labor-inten-
sive organic farming. Young contends, how-
ever, that large-scale organic farming simply
wouldn't be practical as a way to feed all the
people in the United States. And Lemaux
points out that conventional plant breeding
has already dramatically altered the nation's
crops. "Ifyou look at the progenitors ofour
modern-day crops, there probably isn't a
product in the grocery store that looks any-
thing like its wild relatives," she notes.
According to Young, biotechnology should
actually help increase the biodiversity ofU.S.
crops.
Even so, efforts to develop viral-resistant
crops are prompting some scientists to askdif-
ficult environmental questions. Specifically, if
pest-resistant plants can encourage the evolu-
tion ofsuper pests, could viral-resistant crops
promoteextra-potentviruses?
In the 11 March 1994 issueofScience, Ann
E. Greene and Richard F. Allison ofMichigan
State University proposed a mechanism by
whichviruses mightrecombinewiththegenetic
material oftransgenic plants. "As transgenically
expressedviral mRNAis available to recombine
with replication viruses," the authors wrote,
"RNA recombination
c should be considered
2 when analyzing the risks
posed by virus-resistant
, transgenicplants."
A rebuttal to Greene
. and Allison's paper
< appeared in the same
tb issue of Science. "We
believe that it is unlikely - that recombinants be-
tween transgene RNA
rt~ ~-and viral genomnic RNA
t<-f<;111 I will occur at frequencies
Is engineered with greater than they already
sms may lead to a are occurring byrecombi-
as.
Peggy G. Lemaux-Due to conventional plant
breeding, modern crops don't look anything like
theirwild relatives.
nations between virus genomic RNAs in nat-
ural conventional and subliminal infections,"
wrote BryceW. Falkand George Brueningof
the University of California at Davis. "The
potential benefits of engineered resistance
genes far outweigh the vanishingly small risk
ofcreatingnewandharmful viruses."
As researchers continue to ponder the
environmental consequences ofbioengineer-
ing, Jane Rissler ofthe Union ofConcerned
Scientists says the FDA must revamp its
review process to include tough premarket
testing and labeling ofgenetically engineered
foods. "They ought to be devoting their
resources to developing a food policy that
reallydoes protect consumers," she says.
Defined under the direction of former
Vice President Dan Quayle, the FDA's cur-
rent regulatory system isn't fair to consumers
or to companies like Calgene, according to
Marsha Cohen, a law professor at Hastings
College ofthe Law, University ofCalifornia.
Throughout the FDA's lengthy review ofthe
Flavr Savr tomato, Cohen says, "Calgene
didn't know where all the hoops were"
becausepolicies were unclear.
For now, though, the FDA will evaluate
new biofoods on a case-by-case basis,
Maryanski says. And researchers like Lemaux
will keep focusing on the potential benefits of
better barley and other geneticallyengineered
crops. "There are really some fantastic things
that can be done with biotechnology, but
[the science] needs a lifetime to develop,"
Lemaux says. "It shouldn't develop in an
unbounded way, but itshoulddevelop."
Ginger Pinholster
Ginger Pinholster is a freelance writer in
Wilmington, Delaware.
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